Immutep Limited (ASX: IMM) CEO and Executive Director Marc Voigt discusses the FDA fast track designation received in first-line non-small cell lung cancer, the company’s new Phase 2 trial in soft tissue sarcoma and the outlook ahead.
IMM’s objective is to harness and strengthen the power of the body’s own immune systems through therapeutic intervention for the benefit of patients’ health. This is how immunotherapy fights cancer and autoimmune disease.